From the initiation of anti-PD-1 treatment, factors such as tumour mutational burden, specific mutations (e.g., STK11, KEAP), clonal architecture, aneuploidy, immune-escape mechanisms, and interferon-γ signalling pathways have all been linked to resistance [26]. This evidence concerns the gene STK11 and neoplasm.